{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:46:13Z","timestamp":1785757573664,"version":"3.56.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,21]],"date-time":"2027-02-21T00:00:00Z","timestamp":1803168000000},"content-version":"am","delay-in-days":326,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.msard.2026.107082","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T20:27:50Z","timestamp":1771360070000},"page":"107082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Serum metabolomic signatures of relapse recovery in early multiple sclerosis"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-1359","authenticated-orcid":false,"given":"Farren B.S.","family":"Briggs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboobeh","family":"Fereida-Esfahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Sagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Oksenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Gregory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Oliver","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2026.107082_bib0001","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2026.107082_bib0002","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1001\/jamaneurol.2013.599","article-title":"Early relapses, onset of progression, and late outcome in multiple sclerosis","volume":"70","author":"Scalfari","year":"2013","journal-title":"JAMa Neurol."},{"issue":"8","key":"10.1016\/j.msard.2026.107082_bib0003","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1212\/WNL.0000000000001856","article-title":"Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis","volume":"85","author":"Novotna","year":"2015","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2026.107082_bib0004","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1007\/s00415-020-09850-z","article-title":"Predicting onset of secondary-progressive multiple sclerosis using genetic and non-genetic factors","volume":"267","author":"Misicka","year":"2020","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2026.107082_bib0005","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1212\/NXI.0000000000000321","article-title":"Metabolomic signatures associated with disease severity in multiple sclerosis","volume":"4","author":"Villoslada","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.107082_bib0006","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.msard.2019.03.006","article-title":"Metabolome-based signature of disease pathology in MS","volume":"31","author":"Andersen","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2026.107082_bib0007","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1172\/JCI129401","article-title":"Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation","volume":"130","author":"Bhargava","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.msard.2026.107082_bib0008","article-title":"Multi-omic evaluation of metabolic alterations in multiple sclerosis identifies shifts in aromatic amino acid metabolism","volume":"2","author":"Fitzgerald","year":"2021","journal-title":"Cell Rep. Med."},{"issue":"4","key":"10.1016\/j.msard.2026.107082_bib0009","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1177\/13524585251325468","article-title":"Metabolic and lipid alterations in multiple sclerosis linked to disease severity","volume":"31","author":"Noroozi","year":"2025","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.msard.2026.107082_bib0010","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/acn3.52167","article-title":"Ocrelizumab alters the circulating metabolome in people with relapsing-remitting multiple sclerosis","volume":"11","author":"Siavoshi","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2026.107082_bib0011","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1212\/CPJ.0000000000000254","article-title":"Consensus opinion of US neurologists on practice patterns in RIS, CIS, and RRMS: evolution of treatment practices","volume":"6","author":"Tornatore","year":"2016","journal-title":"Neurol. Clin. Pract."},{"issue":"3","key":"10.1016\/j.msard.2026.107082_bib0012","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/01.ede.0000158224.50593.e3","article-title":"The cross-sectional cohort study: an underutilized design","volume":"16","author":"Hudson","year":"2005","journal-title":"Epidemiology"},{"issue":"2","key":"10.1016\/j.msard.2026.107082_bib0013","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107082_bib0014","doi-asserted-by":"crossref","unstructured":"Ryals J., Lawton K., Stevens D., M.M. Metabolon, Inc Pharmacogenomics 2007 Jul;8(7):863\u20136.","DOI":"10.2217\/14622416.8.7.863"},{"key":"10.1016\/j.msard.2026.107082_bib0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random forests","volume":"45","author":"Breiman","year":"2001","journal-title":"Mach. Learn."},{"issue":"1","key":"10.1016\/j.msard.2026.107082_bib0016","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2202\/1544-6115.1691","article-title":"Random forests for genetic association studies","volume":"10","author":"Goldstein","year":"2011","journal-title":"Stat. Appl. Genet. Mol. Biol."},{"issue":"1","key":"10.1016\/j.msard.2026.107082_bib0017","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33077-8","article-title":"Machine-learning based lipid mediator serum concentration patterns allow identification of multiple sclerosis patients with high accuracy","volume":"8","author":"Lotsch","year":"2018","journal-title":"Sci. Rep."},{"issue":"Suppl 1","key":"10.1016\/j.msard.2026.107082_bib0018","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12859-019-3310-7","article-title":"So you think you can PLS-DA?","volume":"21","author":"Ruiz-Perez","year":"2020","journal-title":"BMC Bioinformat."},{"issue":"W1","key":"10.1016\/j.msard.2026.107082_bib0019","doi-asserted-by":"crossref","first-page":"W398","DOI":"10.1093\/nar\/gkae253","article-title":"MetaboAnalyst 6.0: towards a unified platform for metabolomics data processing, analysis and interpretation","volume":"52","author":"Pang","year":"2024","journal-title":"Nucleic. Acids. Res."},{"issue":"8","key":"10.1016\/j.msard.2026.107082_bib0020","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1177\/13524585231171517","article-title":"Several serum lipid metabolites are associated with relapse risk in pediatric-onset multiple sclerosis","volume":"29","author":"Virupakshaiah","year":"2023","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2026.107082_bib0021","doi-asserted-by":"crossref","first-page":"fcab240","DOI":"10.1093\/braincomms\/fcab240","article-title":"Objective biomarkers for clinical relapse in multiple sclerosis: a metabolomics approach","volume":"3","author":"Yeo","year":"2021","journal-title":"Brain Commun."},{"key":"10.1016\/j.msard.2026.107082_bib0022","unstructured":"Christie W. https:\/\/www.lipidmaps.org\/resources\/lipidweb\/lipidweb_html\/lipids\/simple\/carnitin\/index.htm. The lipidweb. 2025."},{"key":"10.1016\/j.msard.2026.107082_bib0023","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/srep00079","article-title":"Inhibition of fatty acid metabolism ameliorates disease activity in an animal model of multiple sclerosis","volume":"1","author":"Shriver","year":"2011","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.msard.2026.107082_bib0024","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-72638-8","article-title":"Dysregulation of metabolic pathways by carnitine palmitoyl-transferase 1 plays a key role in central nervous system disorders: experimental evidence based on animal models","volume":"10","author":"Trabjerg","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.msard.2026.107082_bib0025","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40168-023-01551-9","article-title":"Gut microbiota-derived 3-phenylpropionic acid promotes intestinal epithelial barrier function via AhR signaling","volume":"11","author":"Hu","year":"2023","journal-title":"Microbiome"},{"issue":"10","key":"10.1016\/j.msard.2026.107082_bib0026","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/acn3.637","article-title":"Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course","volume":"5","author":"Nourbakhsh","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2026.107082_bib0027","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1007\/s11064-023-03981-1","article-title":"Pathogenic role of fibrinogen in the neuropathology of Multiple sclerosis: a tale of sorrows and fears","volume":"48","author":"Alruwaili","year":"2023","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.msard.2026.107082_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcn.2023.103887","article-title":"Glutamine metabolism in diseases associated with mitochondrial dysfunction","volume":"126","author":"Bornstein","year":"2023","journal-title":"Mol. Cell Neurosci."},{"issue":"490","key":"10.1016\/j.msard.2026.107082_bib0029","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao5563","article-title":"Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects","volume":"11","author":"Klotz","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.msard.2026.107082_bib0030","article-title":"Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease","volume":"6","author":"Ladakis","year":"2025","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.msard.2026.107082_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040812","article-title":"Myelin fat facts: an overview of lipids and fatty acid metabolism","volume":"9","author":"Poitelon","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.msard.2026.107082_bib0032","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.03141-20","article-title":"Sphingomyelin biosynthesis is essential for phagocytic signaling during mycobacterium tuberculosis host cell entry","volume":"12","author":"Niekamp","year":"2021","journal-title":"mBio"},{"issue":"8","key":"10.1016\/j.msard.2026.107082_bib0033","article-title":"Impact of sphingolipids on protein membrane trafficking","volume":"1868","author":"Aguilera-Romero","year":"2023","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001185?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001185?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:03:22Z","timestamp":1785755002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826001185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":33,"alternative-id":["S2211034826001185"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107082","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum metabolomic signatures of relapse recovery in early multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107082"}}